KNSA

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

92.36

USD

-5.20

-5.33%

Oct 30, 14:30 UTC -4

Open

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Earnings

KNSA Earnings Reports

Positive Surprise Ratio

KNSA beat 19 of 33 last estimates.

58%

Next Report

Date of Next Report

Feb 22, 2027

Estimate for Q4 26 (Revenue/ EPS)

$281.76M

$0.37

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

+39.40%

+117.65%

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares earnings per share and revenue

On Oct 26, 2026, KNSA reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of 0.37 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 265.82 million, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of 0.37 USD, with revenue projected to reach 281.76 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

PTC Therapeutics, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.34

Actual

$0.61

Surprise

+75.59%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Regeneron Pharmaceuticals Inc

Report Date

Oct 30, 2026 For Q3 26

Estimate

$16.47

Actual

$20.07

Surprise

+21.79%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Insmed, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.46

Surprise

-19.82%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares expected to report next?

The next earning report is scheduled for Feb 22, 2027.

What are the forecasts for Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares's next earnings report?

Based on -- analysts, Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares is expected to report EPS of $0.37 and revenue of $281.76M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.